FcRn Antagonist vs Complement Inhibitor — Immunology Deal Terms Comparison
Market Analysis
In immunology, FcRn Antagonist and Complement Inhibitor represent two of the most actively transacted modalities. At Phase 2, FcRn Antagonist deals carry a median total deal value of $3.0B with $583M upfront, compared to $2.9B total value and $560M upfront for Complement Inhibitor. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. FcRn Antagonist development milestones average $491M versus $472M for Complement Inhibitor. Commercial milestones are $1.1B for FcRn Antagonist and $1.1B for Complement Inhibitor. Royalty rates range from 14%-23.4% for FcRn Antagonist and 13.9%-23.1% for Complement Inhibitor.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do FcRn Antagonist and Complement Inhibitor deal terms compare in immunology?
Which modality commands higher royalty rates: FcRn Antagonist or Complement Inhibitor?
How do milestone structures differ between FcRn Antagonist and Complement Inhibitor?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.